Navigation Links
VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
Date:1/8/2010

ROCHESTER, N.Y., Jan. 8 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that Ms. Molly Henderson, the company's chief business and financial officer, will be presenting a corporate overview at the upcoming OneMedPlace Finance Forum at the Sir Francis Drake Hotel in San Francisco. Held annually, the OneMedPlace Finance Forum was created to connect emerging healthcare and life science companies with investors and strategic partners. Ms. Henderson is scheduled to present at 3:30 PM PST on Wednesday, January 13, 2010.

A live webcast of the presentation will be available in the Investor Relations section of the company's website, www.virtualscopics.com. The replay will be available within one hour of the live presentation and will remain available for 30 days following the conference.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.


    CONTACT:         Company Contact:
                     Molly Henderson
                     Chief Business and Financial Officer
                     500 Linden Oaks
                     Rochester, New York 14625
                     (585)249.6231


SOURCE VirtualScopics, Inc.

RELATED LINKS
http://www.virtualscopics.com

'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics Receives Issuance in Japan of Prominent Patent
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... Egg freezing and embryo freezing are both ... slight statistical advantage for live births, frozen eggs offer many advantages, depending on ... medical treatment or who are concerned about the decline of their fertility as ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
Breaking Medicine News(10 mins):